More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are over 25 technology platforms available for use in therapy development effort
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift

The concept of targeted protein degradationpresents revolutionary drug development opportunities and is anticipated tobring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysistargeting chimera (PROTAC), was developed about a decade ago. Presently, avariety of other such chemical entities and molecular glues are underinvestigation. In fact, certain pipeline candidates are already in the mid tolate-phase trials and are anticipated to soon enter the market.


To order this 330+ page report, which features 130+ figuresand 145+ tables, please visit this -


The USD 3.6 billion (by 2030) financial opportunitywithin the target protein degradation market has been analyzed across thefollowing segments:

§ Type of payment oflicensing agreements

§ Upfront payments

§ Milestone payments


§ Type of proteindegrader

§ Degronimids



§ Specific BET and DUBinhibitors

§ Other proteindegraders


§ Therapeutic area

§ Neurodegenerativedisorders

§ Oncological disorders

§ Other therapeuticareas


§ Route ofadministration  

§ Oral

§ Intravenous

§ Other routes


§ Key geographicalregion

§ North America

§ Europe

§ Asia-Pacific


The TargetedProtein Degradation Market: Focus on Therapeutics and Technology Platforms(based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags,IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein HomeostaticModulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors),2020-2030 report features the following companies, which weidentified to be key players in this domain:

§ Arvinas

§ Captor Therapeutics

§ Celgene

§ Genetech

§ Kymera Therapeutics

§ Mission Therapeutics

§ Progenra

§ Radius Health 

§  SanofiGenzyme

§  Zenopharm


Table of Contents


1. Preface

2. Executive Summary

3. Introduction

4. Current Market Landscape

5. Company Profiles

6. Clinical Trial Analysis 

7. KOL Analysis

8. Publication Analysis

9. Funding and Investment Analysis

10. Partnerships and Collaborations

11.  MarketSizing and Opportunity Analysis

12. Executive Insights


13. Concluding Remarks


14. Appendix 1: Tabulated Data


15. Appendix 2: List of Companies andOrganizations


To purchase a copy, please visit


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415